America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 168.58 Thousand USD | 111.36% |
| 2022 | -1.48 Million USD | -2989.42% |
| 2021 | 51.35 Thousand USD | 2339.57% |
| 2020 | 2105.00 USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 215.5 Thousand USD | 1451.9% |
| 2015 | -15.94 Thousand USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 6627.00 USD | 63.87% |
| 2012 | 4044.00 USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 82.65 Thousand USD | 506.37% |
| 2024 Q3 | 82.11 Thousand USD | -0.66% |
| 2024 Q1 | 13.63 Thousand USD | -81.74% |
| 2023 Q4 | 74.65 Thousand USD | 90.15% |
| 2023 FY | 168.58 Thousand USD | 111.36% |
| 2023 Q1 | 24.43 Thousand USD | 126.9% |
| 2023 Q2 | 30.23 Thousand USD | 23.71% |
| 2023 Q3 | 39.26 Thousand USD | 29.87% |
| 2022 Q2 | -1.39 Million USD | 0.0% |
| 2022 FY | -1.48 Million USD | -2989.42% |
| 2022 Q4 | -90.86 Thousand USD | -3911.33% |
| 2022 Q3 | 2384.00 USD | 100.17% |
| 2022 Q1 | - USD | 100.0% |
| 2021 Q3 | 51.63 Thousand USD | 0.0% |
| 2021 Q4 | -269.00 USD | -100.52% |
| 2021 FY | 51.35 Thousand USD | 2339.57% |
| 2021 Q1 | -8.00 USD | -100.38% |
| 2021 Q2 | - USD | 100.0% |
| 2020 FY | 2105.00 USD | 0.0% |
| 2020 Q4 | 2105.00 USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 100.0% |
| 2019 Q4 | -100.00 USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | 100.00 USD | 0.0% |
| 2019 Q2 | - USD | -100.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 100.0% |
| 2017 Q2 | - USD | -100.0% |
| 2017 Q1 | 9888.00 USD | -95.98% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | -42.86 Thousand USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2016 Q2 | 52.77 Thousand USD | 297.59% |
| 2016 Q3 | -96.32 Thousand USD | -282.53% |
| 2016 Q1 | 13.27 Thousand USD | 183.26% |
| 2016 Q4 | 245.78 Thousand USD | 355.16% |
| 2016 FY | 215.5 Thousand USD | 1451.9% |
| 2015 Q2 | -147.69 Thousand USD | 0.0% |
| 2015 Q4 | -15.94 Thousand USD | 89.21% |
| 2015 Q3 | -147.69 Thousand USD | 0.0% |
| 2015 Q1 | -147.69 Thousand USD | 0.0% |
| 2015 FY | -15.94 Thousand USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | 44.72 Thousand USD | 574.92% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q2 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | 6627.00 USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 100.0% |
| 2013 FY | 6627.00 USD | 63.87% |
| 2012 Q2 | 4044.00 USD | 0.0% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | -5206.00 USD | 0.0% |
| 2012 FY | 4044.00 USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 167.435% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 130.597% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 194.712% |
| Better Therapeutics, Inc. | -2.72 Million USD | 106.178% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 112.172% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 60.118% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 100.736% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 116.504% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 102.377% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 165.092% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | 419.913% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 106.03% |
| Molecular Templates, Inc. | 50.39 Million USD | 99.665% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 241.32% |
| NexImmune, Inc. | -1.02 Million USD | 116.448% |
| Orgenesis Inc. | -5.72 Million USD | 102.945% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 100.657% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | 3764.16% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 99.426% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 134.525% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 172.667% |
| Trevena, Inc. | 1.45 Million USD | 88.413% |
| Vaxxinity, Inc. | -2.23 Million USD | 107.546% |
| Vaccinex, Inc. | -16 Million USD | 101.053% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 134.266% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -1352.093% |